Table 1.
Summary of drugs identified as TRAIL sensitizing agents and their previously known activity.
| 10 μM | |||||||
|---|---|---|---|---|---|---|---|
| Drug Name | Drug Alone |
Drug Alone + TRAIL Alone (Additive) |
Combination Treatment | p-Value | Known TRAIL Sensitizer? | Known TRAIL Sensitizer in Prostate Cancer? | Known TRAIL Sensitizer in Pancreatic Cancer? |
| Daunorubicin | 47 | 51.3 | 95.6 | < 0.01 | Yes | No | No |
| Docetaxel | 31.2 | 35.5 | 72.7 | < 0.01 | Yes | Yes | No |
| Doxorubicin | 39 | 43.3 | 90.8 | < 0.01 | Yes | Yes | Yes |
| Epirubicin | 34.7 | 39 | 58.7 | < 0.05 | Yes | Yes | No |
| Fludarabine | 58.6 | 62.9 | 86.2 | < 0.05 | Yes | No | No |
| Idarubicin | 53.3 | 57.6 | 97.7 | < 0.01 | No | No | No |
| Irinotecan | 30.6 | 34.9 | 65.4 | < 0.01 | Yes | Yes | No |
| Mithramycin | 28.6 | 32.9 | 95 | < 0.01 | Yes | Yes | No |
| Mitoxantrone | 52.2 | 56.5 | 97.7 | < 0.01 | No | No | No |
| 20 μM | |||||||
| Cladribine | 0 | 4.1 | 38.5 | < 0.05 | No | No | No |
| Cytarabine | 7.9 | 12.2 | 32.9 | < 0.05 | No | No | No |
| Gemcitabine | 28.4 | 32.7 | 70.5 | < 0.01 | Yes | Yes | Yes |
| Thioguanine | 4.7 | 9 | 40.8 | < 0.05 | No | No | No |
| Thiotepa | 6.2 | 10.5 | 47.2 | < 0.01 | No | No | No |
Values are listed as mean percent viability reduction. Leads employed in an expanded dose response are shown in bold font.